Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 14;8(4):978-1012.
doi: 10.1021/acsptsci.4c00726. eCollection 2025 Apr 11.

Recommended Tool Compounds: Thienotriazolodiazepines-Derivatized Chemical Probes to Target BET Bromodomains

Affiliations
Review

Recommended Tool Compounds: Thienotriazolodiazepines-Derivatized Chemical Probes to Target BET Bromodomains

Chuhui Huang et al. ACS Pharmacol Transl Sci. .

Abstract

Thienotriazolodiazepines, including (+)-JQ1 (4), are well-known inhibitors of the bromodomain (BD) and extra-terminal domain (BET) family of proteins. Despite the suboptimal physicochemical properties as a drug candidate, such as poor solubility and half-life, (+)-JQ1 (4) has proven as an effective chemical probe with high target potency and selectivity. (+)-JQ1 (4) and (+)-JQ1-derived chemical probes have played a vital role in chemical biology and drug discovery over the past decade, which is demonstrated by the high number of impactful research studies published since the disclosure of (+)-JQ1 (4) in 2010. In this review, we discuss the development of (+)-JQ1-derivatized chemical probes over the past decade and their significant contribution to scientific research. Specifically, we will summarize the development of innovative label-free and labeled (+)-JQ1-derivatized chemical probes, such as bivalent, covalent, and photoaffinity probes as well as protein degraders, with a focus on the design of these chemical probes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Similar articles

Cited by

References

    1. Langley M. S.; Clissold S. P. Brotizolam: A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy as an Hypnotic. Drugs 1988, 35 (2), 104–122. 10.2165/00003495-198835020-00002. - DOI - PubMed
    1. Nielsen S.; McAuley A. Etizolam: A Rapid Review on Pharmacology, Non-medical Use and Harms. Drug and Alcohol Review 2020, 39 (4), 330–336. 10.1111/dar.13052. - DOI - PubMed
    1. Miyoshi S.; Ooike S.; Iwata K.; Hikawa H.; Sugahara K.. Antitumor Agent. Patent WO2009084693, 2009. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009084693.
    1. Zhang G.; Liu R.; Zhong Y.; Plotnikov A. N.; Zhang W.; Zeng L.; Rusinova E.; Gerona-Nevarro G.; Moshkina N.; Joshua J.; Chuang P. Y.; Ohlmeyer M.; He J. C.; Zhou M.-M. Down-Regulation of NF-κB Transcriptional Activity in HIV-Associated Kidney Disease by BRD4 Inhibition. J. Biol. Chem. 2012, 287 (34), 28840–28851. 10.1074/jbc.M112.359505. - DOI - PMC - PubMed
    1. Hu Y.; Zhou J.; Ye F.; Xiong H.; Peng L.; Zheng Z.; Xu F.; Cui M.; Wei C.; Wang X.; Wang Z.; Zhu H.; Lee P.; Zhou M.; Jiang B.; Zhang D. BRD4 Inhibitor Inhibits Colorectal Cancer Growth and Metastasis. IJMS 2015, 16 (1), 1928–1948. 10.3390/ijms16011928. - DOI - PMC - PubMed

LinkOut - more resources